Lipoprotein-associated phospholipase A2 antibody compositions and methods of use
The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
1. An isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment binds to Lp-PLA2 and comprises:
a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 12, and 22; and
a heavy chain variable region.
2. An isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment binds to Lp-PLA2 and comprises:
a light chain variable region; and
a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 17, and 27.
3. The antibody or antigen binding fragment of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2; and wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7.
4. The antibody or antigen binding fragment of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 12; and wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 17.
5. The antibody or antigen binding fragment of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 22; and wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 27.
6. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment is a monoclonal antibody.
7. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment is a chimeric antibody.
8. An isolated monoclonal antibody or antigen binding fragment thereof that binds to Lp-PLA2, the antibody or antigen binding fragment comprising: a light chain variable region comprising CDR1, CDR2 and CDR3 sequences; and a heavy chain variable region comprising CDR1, CDR2, CDR3 sequences, wherein:
(a) the light chain variable region comprises:
a light chain CDR1 having an amino acid sequence of SEQ ID NO: 3,
a light chain CDR2 having an amino acid sequence of SEQ ID NO: 4,
a light chain CDR3 having an amino acid sequence of SEQ ID NO: 5; and
(b) the heavy chain variable region comprises:
a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 8,
a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 9,
a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 10.
9. The antibody of claim 8 , wherein the antibody is a humanized antibody or a chimeric antibody.
10. An isolated monoclonal antibody or antigen binding fragment thereof that binds to Lp-PLA2, the antibody or antigen binding fragment comprising: a light chain variable region comprising CDR1, CDR2 and CDR3 sequences; and a heavy chain variable region comprising CDR1, CDR2, CDR3 sequences, wherein:
(a) the light chain variable region comprises:
a light chain CDR1 having an amino acid sequence of SEQ ID NO: 13,
a light chain CDR2 having an amino acid sequence of SEQ ID NO: 14,
a light chain CDR3 having an amino acid sequence of SEQ ID NO: 15; and
(b) the heavy chain variable region comprises:
a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 18,
a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 19,
a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 20.
11. The antibody of claim 10 , wherein the antibody is a humanized antibody or a chimeric antibody.
12. An isolated monoclonal antibody or antigen binding fragment thereof that binds to Lp-PLA2, the antibody or antigen binding fragment comprising: a light chain variable region comprising CDR1, CDR2 and CDR3 sequences; and a heavy chain variable region comprising CDR1, CDR2, CDR3 sequences, wherein:
(a) the light chain variable region comprises:
a light chain CDR1 having an amino acid sequence of SEQ ID NO: 23,
a light chain CDR2 having an amino acid sequence of SEQ ID NO: 24,
a light chain CDR3 having an amino acid sequence of SEQ ID NO: 25; and
(b) the heavy chain variable region comprises:
a heavy chain CDR1 having an amino acid sequence of SEQ ID NO: 28,
a heavy chain CDR2 having an amino acid sequence of SEQ ID NO: 29,
a heavy chain CDR3 having an amino acid sequence of SEQ ID NO: 30.
13. The antibody of claim 12 , wherein the antibody is a humanized antibody or a chimeric antibody.